BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
VANCOUVER, BC / ACCESSWIRE / December 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience company specializing in advanced drug delivery systems, has achieved key milestones in the development of BNT23001, its proprietary sublingual thin-film (OFD) formulation of Cladribine for the treatment of Multiple Sclerosis (MS). These achievements in 2024 lay the groundwork for clinical trials and regulatory submissions in 2025, reinforcing BioNxt's commitment to advancing patient-centric therapeutic solutions.
2024 Milestones: Establishing a Strong Foundation for Cladribine Thin-Film Development
Preclinical Success: BNT23001 demonstrated high absorption rates of Cladribine through sublingual delivery in pharmacokinetic (PK) studies conducted in animal models. These studies confirmed the product's bioequivalence to the originator therapy, Mavenclad®, and validated the thin-film's rapid absorption and safety profile. Toxicity studies further demonstrated no adverse local effects, highlighting the viability of the sublingual delivery approach.
Advancements in Manufacturing: BioNxt successfully transferred the BNT23001 production process to its GMP-certified manufacturing partner, Gen-Plus GmbH & Co KG in Munich (Germany), ensuring readiness for clinical batch production. This milestone supports the Company's plan to initiate clinical trials in 2025 with reliable, high-quality product supply.
Strengthened Intellectual Property Position: A favorable International Preliminary Report on Patentability (IPRP) confirmed BNT23001's novelty, inventive step, and industrial applicability, underscoring its unique value in MS treatment. The Company has initiated patent nationalization in major jurisdictions, including Europe, the United States, and Canada, with patent grants anticipated in several regions by mid-2025.
2025 Roadmap: Advancing BNT23001 into Clinical Trials
Manufacturing Clinical Batches: BioNxt will complete GMP manufacturing and Qualified Person (QP) release of clinical trial batches in the second quarter of 2025. This step is critical for the successful initiation of human studies.
Regulatory Filings and Approvals: The Company plans to submit the Investigational Medicinal Product Dossier (IMPD) to European regulatory authorities by mid-2025, paving the way for clinical trial approval. These regulatory submissions will include data from preclinical studies and stability assessments conducted at the manufacturing site.
Clinical Study to Validate Performance: BioNxt aims to launch a pilot clinical study in the latter half of 2025. This trial will compare the efficacy, bioavailability, and safety of BNT23001 to Mavenclad®, the originator tablet product, positioning the thin-film formulation as a patient-friendly alternative.
Ongoing Patent Protection: In addition to continuing the patent nationalization process, BioNxt expects granted patents in key regions to strengthen its intellectual property portfolio and provide competitive advantages as the product moves toward commercialization.
BNT23001: Advancing Toward Clinical Validation for MS Treatment
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
• Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
• Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
• Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 780-818-6422
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BNT23001, as well as projected milestones for 2025. These statements are based on current expectations and assumptions but involve risks and uncertainties that could cause actual results to differ materially. These risks include clinical trial outcomes, regulatory delays, manufacturing challenges, intellectual property issues, market competition, and changes in laws or market conditions. The Company undertakes no obligation to update or revise forward-looking statements, except as required by law. For more information, refer to the "Risk Factors" section of the Company's filings at www.sedarplus.ca.
Trademarks: Mavenclad® is a registered trademark of EMD Serono, Inc. BioNxt Solutions Inc. is not affiliated with or endorsed by EMD Serono.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Sauce Labs and Deque Systems Partner to Deliver Comprehensive Accessibility Testing at Scale24.10.2025 07:00:00 CEST | Press release
SAN FRANCISCO, CA / ACCESS Newswire / October 24, 2025 / Sauce Labs Inc., a leading provider of continuous testing solutions, and Deque Systems, Inc., a trusted leader in digital accessibility, today announced a strategic partnership to help companies ensure compliance with accessibility regulations and deliver accessible digital experiences across all devices and platforms. The collaboration combines Sauce Labs' extensive real-device coverage and scalable cloud infrastructure with Deque's unparalleled accessibility expertise. This partnership is a renewed commitment, building on a long-standing relationship between the two companies. By doubling down on their joint offering, Sauce Labs and Deque are providing a comprehensive solution for accessibility testing at scale. The partnership addresses the growing need for businesses to meet digital accessibility standards, especially with the upcoming European Accessibility Act (EAA), which became law on June 28, 2025. The EAA requires produ
Florence Connects 65,000+ Study Sites and 600+ Sponsors Worldwide - Unleashing the Next Era of Clinical Trial Intelligence23.10.2025 14:00:00 CEST | Press release
With the industry's largest network of sites, Florence sets a new benchmark for AI-enabled study startup, workflow automation, and operational risk management. ATLANTA, GA / ACCESS Newswire / October 23, 2025 / Florence Healthcare reinforced its position as the global leader in clinical trial operations with a major milestone: Florence Trial Operations Platform now connects 65,000 study sites spanning more than 600 sponsors across 90+ countries, forming the industry's largest network. Recognized as the #1 clinical trial technology for six consecutive years, Florence continues to set the standard for startup speed, workflow automation, and operational risk management across sponsor study portfolios. "Florence was built to bring sponsors and sites into a shared operational space," said Ryan Jones, CEO of Florence Healthcare. "First, we fully digitized startup to eliminate manual bottlenecks and paper workflows. Now, we're using AI to enhance speed and augment intelligence across 65,000 s
U.S. Polo Assn. Wins Gold and Silver Stevie Awards at the 2025 International Business Awards in Lisbon, Portugal23.10.2025 13:00:00 CEST | Press release
LISBON, PT AND WEST PALM BEACH, FL / ACCESS Newswire / October 23, 2025 / USPA Global today announced that U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has been awarded two prestigious Stevie® Awards from the 22nd Annual International Business Awards® (IBA).U.S. Polo Assn. Wins Two Stevie® Awards U.S. Polo Assn. was celebrated during an elegant gala event at the Corinthia Hotel in Lisbon, Portugal, on Friday, October 10, attended by leadership from USPA Global and the brand's strategic partners in the region. The global event hosted over 350 guests from more than 30 nations, including many of the world's top companies and Stevie winners, including Coca-Cola, Starbucks, Lenovo, Kendra Scott, IBM, and Turkish Airlines. The brand's winning entries included a Gold Stevie Award for 'Achievement in International Expansion' and a Silver Stevie Award in 'Celebration Event' for the 2024 Paris Games Polo Challenge campaign. The multi-billion-dollar, sp
Fortune 500 Leaders Share AI-powered Supply Chain Excellence on Stage at OMP Conference22.10.2025 11:00:00 CEST | Press release
Industry giants, including AstraZeneca, Johnson & Johnson, General Mills, and Kraft Heinz, to present real-world case studies in Miami MIAMI, FL / ACCESS Newswire / October 22, 2025 / OMP, a global leader in supply chain planning solutions, announced its lineup of customer speakers for the OMP REAL Conference 2025, taking place November 18-19 in Miami. The event will gather industry leaders, technology innovators, and supply chain experts to share how AI-powered supply chain planning delivers real business results. Speakers include executives from world-leading organizations, including Arxada,AstraZeneca, Beiersdorf, Eastman, Johnson & Johnson, Kraft Heinz, Land O'Lakes, and Visy. They will share real-world case studies of how they're leveraging OMP's Unison Planning™ to boost supply chain agility, resilience, and sustainability. Explore the program. Conference theme: REAL This year's theme - Real expertise. Real solutions. Real results. - underscores OMP's commitment to deliver tangib
Oman Hosts the Oman Investment Forum 2025 in the United Kingdom22.10.2025 08:00:00 CEST | Press release
Reform Metrics and Global Outlook Underpin London Gathering LONDON, UK, OM / ACCESS Newswire / October 22, 2025 / The Sultanate of Oman, represented by the Ministry of Finance in cooperation with the Ministry of Foreign Affairs, held the Oman Investment Forum 2025 in London to deepen financial, investment, and economic cooperation between the two nations. The event underscored the strategic weight of the Oman-UK partnership and the role of the Strategic Advisory Group (SAG), established in 2018 as the institutional mechanism through which the two countries coordinate investment, fiscal reform, and economic-diversification strategy. Oman enters this year's forum with one of the strongest fiscal positions in the region. Foreign Direct Investment (FDI) reached USD 78.8 billion by the end of the second quarter of 2025, a 12.8 percent increase compared to 2024. Inflows during the first half of 2025 totalled USD 8.8 billion, reflecting rising international confidence. Omani officials opened
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom